The drug combination tested in the trial included interferon beta-1b, which was developed to treat multiple sclerosis (MS), and lopinavir-ritonavir, which is normally used to treat HIV and ribavirin, an oral hepatitis C virus drug
A two-week course of antiviral therapy that combines the power of three drugs has shown promise in treating hospitalised patients with mild to moderate COVID-19 in a carefully undertaken phase 2 clinical trial.
ADVERTISEMENT
The results of the trial, published in the journal The Lancet, involved 127 adults from six public hospitals in Hong Kong.
The drug combination tested in the trial included interferon beta-1b, which was developed to treat multiple sclerosis (MS), and lopinavir-ritonavir, which is normally used to treat HIV and ribavirin, an oral hepatitis C virus drug.
The findings of the phase two trial provided evidence that early treatment with triple antiviral therapy alongside standard care is safe and shortens duration of viral shedding (when the virus is detectable and potentially transmissible) compared to lopinavir-ritonavir alone—average seven days vs 12 days—in patients with mild to moderate COVID-19.
"Our trial demonstrates that early treatment of mild to moderate COVID-19 with a triple combination of antiviral drugs may rapidly suppress the amount of virus in a patient's body, relieve symptoms, and reduce the risk to healthcare workers by reducing the duration and quantity of viral shedding," said professor Kwok-Yung Yuen from the University of Hong Kong who led the research.
No new cases in Hong Kong as restrictions ease
Hong Kong recorded no new COVID-19 case on Saturday, a day after the city eased restrictions. Saturday was also the 20th day in a row with no local infections. Health experts earlier suggested that Hong Kong could be considered to be free of local transmission if there were no such cases after 28 days.
Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.
Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever
Subscribe today by clicking the link and stay updated with the latest news!" Click here!
